Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy - ADRIATIC

Inclusion Criteria

• 1. Histologically or cytologically documented limited-stage small cell lung cancer (stage I-III).
• 2. Received 4 cycles of chemotherapy concurrent with radiotherapy, which must be completed within 1 to 42 days prior to randomization and the first dose of IP. Chemotherapy must contain platinum and IV etoposide. Radiotherapy must be either total 60-66 Gy over 6 weeks for the standard QD regimen or total 45 Gy over 3 weeks for hyperfractionated BD schedules.
• 3. PCI may be delivered at the discretion of investigator and local standard of care, and must be conducted after the end of cCRT and completed between 1 to 42 days to first dose of IP.
• 4 .Have not progressed following definitive concurrent chemoradiation
• 5 .Life expectancy ≥ 12 weeks at Day 1.
• 6. ECOG 0 or 1 at enrolment.